The 64th ASH (American Society of Hematology) Annu
Post# of 145766
![](/assets/46931549/no_avatar_available_thumb.jpg)
Abedi: Cytodyn: Current equity holder in publicly-traded company; Celgene: Consultancy, Speakers Bureau; Orca Bio: Research Funding; Kite, a Gilead Company: Speakers Bureau; AbbieVie: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau.
He is with the Department of Internal Medicine, Division of Cellular Therapy, Bone Marrow Transplantation and Malignant Hematology, University of California Davis School of Medicine, Sacramento, CA.
This is what is noted about him on their website:
Dr. Abedi's clinical interest is in the area of bone marrow transplantation and in the treatment of refractory/relapsed hematological malignancies and genetic disease. He is also interested in using cellular therapy for treatment of a variety of medical disorders.
Dr. Abedi's basic science research interest is in the area of hematopoietic stem cells and novel models of bone marrow transplantation, and also gene and cellular therapy.
https://health.ucdavis.edu/cancer/team/1329/m...acramento/
Link for ASH meeting
https://www.hematology.org/Meetings/Annual-Meeting
Nice to have a doctor with his pedigree as a stockholder.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)